These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 36894866)
21. Treatment Patterns in Newly Diagnosed Patients with Crohn's Disease Who Received Biologics Following Diagnosis: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Medical Claims Database in Japan. Hirai F; Uda A; Ota M; Takemura Y; Tanaka K; Iwakiri R Digestion; 2023; 104(2):109-120. PubMed ID: 36450239 [TBL] [Abstract][Full Text] [Related]
22. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487 [TBL] [Abstract][Full Text] [Related]
23. Budesonide for maintenance of remission in Crohn's disease. Kuenzig ME; Rezaie A; Seow CH; Otley AR; Steinhart AH; Griffiths AM; Kaplan GG; Benchimol EI Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD002913. PubMed ID: 25141071 [TBL] [Abstract][Full Text] [Related]
24. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. Ma C; Dutton SJ; Cipriano LE; Singh S; Parker CE; Nguyen TM; Guizzetti L; Gregor JC; Chande N; Hindryckx P; Feagan BG; Jairath V Aliment Pharmacol Ther; 2018 Jul; 48(2):114-126. PubMed ID: 29851091 [TBL] [Abstract][Full Text] [Related]
25. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Chande N; Townsend CM; Parker CE; MacDonald JK Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843 [TBL] [Abstract][Full Text] [Related]
26. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Schreiber S; Howaldt S; Raedler A Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910 [TBL] [Abstract][Full Text] [Related]
27. Traditional corticosteroids for induction of remission in Crohn's disease. Benchimol EI; Seow CH; Steinhart AH; Griffiths AM Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006792. PubMed ID: 18425970 [TBL] [Abstract][Full Text] [Related]
28. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Akobeng AK; Gardener E Cochrane Database Syst Rev; 2005 Jan; (1):CD003715. PubMed ID: 15674913 [TBL] [Abstract][Full Text] [Related]
29. Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. Ma C; Ascoytia C; McCarrier KP; Martin M; Feagan BG; Jairath V Dig Dis Sci; 2018 Oct; 63(10):2555-2563. PubMed ID: 29959726 [TBL] [Abstract][Full Text] [Related]
30. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease. Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699 [TBL] [Abstract][Full Text] [Related]
31. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Ford AC; Khan KJ; Talley NJ; Moayyedi P Am J Gastroenterol; 2011 Mar; 106(3):413-20. PubMed ID: 20717106 [TBL] [Abstract][Full Text] [Related]
32. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. de Franchis R; Omodei P; Ranzi T; Brignola C; Rocca R; Prada A; Pera A; Vecchi M; Del Piano M; Ferrara A; Belloli C; Piodi L; Framarin L; Astegiano M; Riccioli FA; Meucci G Aliment Pharmacol Ther; 1997 Oct; 11(5):845-52. PubMed ID: 9354191 [TBL] [Abstract][Full Text] [Related]
33. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500 [TBL] [Abstract][Full Text] [Related]
34. Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Levesque BG; Kane SV Gastroenterol Hepatol (N Y); 2011 May; 7(5):295-301. PubMed ID: 21857830 [TBL] [Abstract][Full Text] [Related]
35. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related]
36. 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. Gearry RB; Ajlouni Y; Nandurkar S; Iser JH; Gibson PR Inflamm Bowel Dis; 2007 Aug; 13(8):1009-15. PubMed ID: 17352386 [TBL] [Abstract][Full Text] [Related]
37. Cannabis for the treatment of Crohn's disease. Kafil TS; Nguyen TM; MacDonald JK; Chande N Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616 [TBL] [Abstract][Full Text] [Related]
38. Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics-A Nationwide Study From the Epi-IIRN. Atia O; Orlanski-Meyer E; Lujan R; Ledderman N; Greenfeld S; Kariv R; Daher S; Yanai H; Loewenberg Weisband Y; Gabay H; Matz E; Nevo D; Israeli E; Schwartz D; Chowers Y; Dotan I; Turner D J Crohns Colitis; 2022 Jun; 16(5):778-785. PubMed ID: 34791083 [TBL] [Abstract][Full Text] [Related]
39. The effectiveness of budesonide therapy for Crohn's disease. Kane SV; Schoenfeld P; Sandborn WJ; Tremaine W; Hofer T; Feagan BG Aliment Pharmacol Ther; 2002 Aug; 16(8):1509-17. PubMed ID: 12182751 [TBL] [Abstract][Full Text] [Related]
40. Durability of Adalimumab and Infliximab in Children With Crohn's Disease: A Nationwide Comparison From the epi-IIRN Cohort. Atia O; Friss C; Focht G; Magen Rimon R; Ledderman N; Ben-Tov A; Loewenberg Weisband Y; Matz E; Gorelik Y; Chowers Y; Dotan I; Turner D Inflamm Bowel Dis; 2024 Nov; 30(11):2097-2104. PubMed ID: 38190498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]